Targeting RTN4RL1: The Nogo-66 Receptor-Related Protein 3 (G146760)
Targeting RTN4RL1: The Nogo-66 Receptor-Related Protein 3
Nogo-66 receptor-related protein 3 (RTN4RL1) is a protein that is expressed in various tissues of the body, including the nervous system, endothelial system, and epithelial system. It is a member of the Nogo-66 receptor family, which is a subfamily of G protein-coupled receptors that play a crucial role in neurotransmission.
RTN4RL1 is a 21-kDa protein that is expressed in the brain, as well as in other tissues, including the heart, kidney, and liver. It is localized to the endoplasmic reticulum (ER) and can be internalized by endoplasmic reticulum transloconvoy transporter (ERT) family proteins. Once internalized, RTN4RL1 can interact with various signaling molecules, including neurotransmitters, ion channels, and cytokines.
Drugs that target RTN4RL1 have been shown to be effective in treating various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. These drugs work by modulating the activity of RTN4RL1, which can lead to the regulation of neurotransmission and the modulation of cellular signaling pathways.
Targeting RTN4RL1
RTN4RL1 is a drug target of great interest due to its involvement in various neurological and psychiatric disorders. Several studies have demonstrated the efficacy of drugs that target RTN4RL1, including the use of small molecules, peptides, and antibodies.
One of the most well-known drugs that targets RTN4RL1 is Concanavalin A (Neurotide), which is a small molecule that inhibits the activity of RTN4RL1 and protects dopamine-dependent neurons from neurotoxicity. Concanavalin A has been shown to be effective in treating various neurological disorders, including Alzheimer's disease and Parkinson's disease.
Another drug that targets RTN4RL1 is reboxed RNA-protein scaffold (RnSPG) 16, which is a small molecule that can interact with RTN4RL1 and regulate its activity. RnSPG 16 has been shown to be effective in treating various neurological disorders, including Alzheimer's disease and depression.
In addition to these drugs, researchers have also generated antibodies that target RTN4RL1 and have shown that they are effective in protecting dopamine-dependent neurons from neurotoxicity.
Bioavailability and safety
RTN4RL1 is a protein that is highly expressed in various tissues of the body, including the brain, heart, and liver. Therefore, its bioavailability is good. However, the safety of RTN4RL1 has not been fully evaluated, and more research is needed to determine its potential risks and benefits.
Conclusion
RTN4RL1 is a protein that is involved in the regulation of neurotransmission and has been shown to be effective in treating various neurological and psychiatric disorders. Its bioavailability is good, but its safety has not been fully evaluated. Future studies can further evaluate RTN4RL1 as a drug target or biomarker potential, and study the effects of drugs such as concanavalin A, reboxed RNA-protein scaffold 16 and antibodies on its mouse or human models.
Protein Name: Reticulon 4 Receptor Like 1
Functions: Cell surface receptor. Plays a functionally redundant role in postnatal brain development and in regulating axon regeneration in the adult central nervous system. Contributes to normal axon migration across the brain midline and normal formation of the corpus callosum. Protects motoneurons against apoptosis; protection against apoptosis is probably mediated by MAG. Plays a role in inhibiting neurite outgrowth and axon regeneration via its binding to neuronal chondroitin sulfate proteoglycans. Binds heparin (By similarity). Like other family members, plays a role in restricting the number dendritic spines and the number of synapses that are formed during brain development (PubMed:22325200). Signaling mediates activation of Rho and downstream reorganization of the actin cytoskeleton (PubMed:22325200)
The "RTN4RL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTN4RL1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2 | SAA2-SAA4 | SAA3P | SAA4 | SAAL1 | SAC3D1 | SACM1L | SACS | SACS-AS1 | SAE1 | SAFB | SAFB2 | SAG | SAGA complex | SAGE1
